Oncolytic adenoviruses in bladder and kidney cancers: emerging strategies and next frontiers

Area of Science:

• Oncolytic virotherapy
• Cancer gene therapy
• Urologic oncology

Background:

• Oncolytic adenoviruses (OAds) are engineered viruses that selectively infect and kill cancer cells.
• Significant progress has been made in tailoring OAds for enhanced antitumor specificity and efficacy.
• Understanding adenovirus biology, cancer pathology, and tumor immunology is crucial for OAd development.

Purpose of the Study:

• To review recent advances in engineered oncolytic adenoviruses for renal and bladder cancers.
• To summarize preclinical and clinical findings on OAd safety and efficacy.
• To highlight the therapeutic potential of OAds for patients with limited treatment options.

Main Methods:

• Review of current literature on oncolytic adenovirus engineering.
• Analysis of preclinical studies in animal models of renal and bladder cancer.
• Summary of clinical trial data on OAd safety and efficacy in cancer patients.

Main Results:

• Engineered OAds demonstrate enhanced antitumor specificity and efficacy.
• Combination therapies involving OAds show synergistic effects.
• Preclinical studies show tumor suppression, and clinical trials indicate favorable safety and efficacy.

Conclusions:

• Engineered oncolytic adenoviruses represent a promising novel therapeutic strategy.
• OAds offer significant potential for treating renal and bladder cancers.
• Further development and clinical application of OAds are warranted for patients with limited options.